;PMID: 9305595
;source_file_1221.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..145] = [t:36..145]
;2)section:[e:149..255] = [t:149..255]
;3)section:[e:259..345] = [t:259..345]
;4)sentence:[e:349..506] = [t:349..506]
;5)sentence:[e:508..816] = [t:508..816]
;6)sentence:[e:817..1020] = [t:817..1020]
;7)sentence:[e:1021..1214] = [t:1021..1214]
;8)sentence:[e:1215..1307] = [t:1215..1307]
;9)sentence:[e:1308..1547] = [t:1308..1547]
;10)sentence:[e:1548..1690] = [t:1548..1690]
;11)sentence:[e:1691..1740] = [t:1691..1740]
;12)sentence:[e:1742..1954] = [t:1742..1954]
;13)section:[e:1958..2002] = [t:1958..2002]

;section 0 Span:0..31
;Leukemia  1997 Sep;11(9):1442-6
(SEC
  (FRAG (IN:[0..8] Leukemia) (CD:[10..14] 1997) (CC:[15..22] Sep;11-LRB-)
        (CD:[22..23] 9) (-RRB-:[23..24] -RRB-) (CD:[24..29] :1442)
        (::[29..30] -) (CD:[30..31] 6)))

;sentence 1 Span:36..145
;Tandem duplications of the FLT3 receptor gene are associated with leukemic 
;transformation of myelodysplasia.
;[36..55]:variation-type:"Tandem duplications"
;[63..76]:gene-rna:"FLT3 receptor"
;[130..144]:malignancy:"myelodysplasia"
(SENT
  (S-HLN
    (NP-SBJ-1
      (NP (JJ:[36..42] Tandem) (NNS:[43..55] duplications))
      (PP (IN:[56..58] of)
        (NP (DT:[59..62] the)
          (NML (NN:[63..67] FLT3) (NN:[68..76] receptor))
          (NN:[77..81] gene))))
    (VP (VBP:[82..85] are)
      (VP (VBN:[86..96] associated)
        (NP-1 (-NONE-:[96..96] *))
        (PP-CLR (IN:[97..101] with)
          (NP
            (NP (JJ:[102..110] leukemic) (NN:[112..126] transformation))
            (PP (IN:[127..129] of)
              (NP (NN:[130..144] myelodysplasia)))))))
    (.:[144..145] .)))

;section 2 Span:149..255
;Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, Taniwaki M, Kashima
;K,  Fujii H, Abe T, Misawa S.
(SEC
  (FRAG (NNP:[149..156] Horiike) (NNP:[157..159] S,) (NNP:[160..166] Yokota)
        (NNP:[167..169] S,) (NNP:[170..175] Nakao) (NNP:[176..178] M,)
        (NNP:[179..183] Iwai) (NNP:[184..185] T) (,:[185..186] ,)
        (NNP:[187..192] Sasai) (NNP:[193..194] Y) (,:[194..195] ,)
        (NNP:[196..202] Kaneko) (NNP:[203..204] H) (,:[204..205] ,)
        (NNP:[206..214] Taniwaki) (NNP:[215..217] M,) (NNP:[218..225] Kashima)
        (NNP:[226..227] K) (,:[227..228] ,) (NNP:[230..235] Fujii)
        (NNP:[236..237] H) (,:[237..238] ,) (NNP:[239..242] Abe)
        (NNP:[243..244] T) (,:[244..245] ,) (NNP:[246..252] Misawa)
        (NNP:[253..255] S.)))

;section 3 Span:259..345
;Department of Internal Medicine III, Kyoto Prefectural University of
;Medicine,  Japan.
(SEC
  (FRAG (NNP:[259..269] Department) (IN:[270..272] of) (NNP:[273..281] Internal)
        (NNP:[282..290] Medicine) (NNP:[291..294] III) (,:[294..295] ,)
        (NNP:[296..301] Kyoto) (NNP:[302..313] Prefectural)
        (NNP:[314..324] University) (IN:[325..327] of) (NNP:[328..336] Medicine)
        (,:[336..337] ,) (NNP:[339..344] Japan) (.:[344..345] .)))

;sentence 4 Span:349..506
;We recently reported an internal tandem duplication of the human flt3
;receptor  gene (FLT3) as a somatic mutation in 17% of acute myelogenous
;leukemia (AML).
;[382..400]:variation-type:"tandem duplication"
;[414..427]:gene-rna:"flt3 receptor"
;[435..439]:gene-rna:"FLT3"
;[454..462]:variation-event:"mutation"
;[473..499]:malignancy:"acute myelogenous leukemia"
;[501..504]:malignancy:"AML"
(SENT
  (S
    (NP-SBJ (PRP:[349..351] We))
    (ADVP-TMP (RB:[352..360] recently))
    (VP (VBD:[361..369] reported)
      (NP
        (NP (DT:[370..372] an) (JJ:[373..381] internal)
           (JJ:[382..388] tandem) (NN:[389..400] duplication))
        (PP (IN:[401..403] of)
          (NP
            (NP (DT:[404..407] the) (JJ:[408..413] human)
              (NML (NN:[414..418] flt3) (NN:[419..427] receptor))
              (NN:[429..433] gene))
            (NP (-LRB-:[434..435] -LRB-) (NN:[435..439] FLT3)
                (-RRB-:[439..440] -RRB-)))))
      (PP (IN:[441..443] as)
        (NP (DT:[444..445] a) (JJ:[446..453] somatic) (NN:[454..462] mutation)))
      (PP (IN:[463..465] in)
        (NP
          (NP (CD:[466..468] 17) (NN:[468..469] %))
          (PP (IN:[470..472] of)
            (NP
              (NP (JJ:[473..478] acute) (JJ:[479..490] myelogenous)
                  (NN:[491..499] leukemia))
              (NP (-LRB-:[500..501] -LRB-) (NN:[501..504] AML)
                  (-RRB-:[504..505] -RRB-)))))))
    (.:[505..506] .)))

;sentence 5 Span:508..816
;The present study revealed the duplication at the juxtamembrane and the first
; tyrosine kinase domains of FLT3 in seven of 92 (8%) patients with 
;myelodysplastic syndrome (MDS) and AML with trilineage myelodysplasia 
;(AML/TMDS), the diseases which may represent neoplastic changes of
;pluripotent  stem cells.
;[539..550]:variation-type:"duplication"
;[614..618]:gene-rna:"FLT3"
;[654..678]:malignancy:"myelodysplastic syndrome"
;[680..683]:malignancy:"MDS"
;[689..692]:malignancy:"AML"
;[698..723]:malignancy:"trilineage myelodysplasia"
;[726..729]:malignancy:"AML"
;[730..734]:malignancy:"TMDS"
(SENT
  (S
    (NP-SBJ (DT:[508..511] The) (JJ:[512..519] present) (NN:[520..525] study))
    (VP (VBD:[526..534] revealed)
      (NP (DT:[535..538] the) (NN:[539..550] duplication))
      (PP-LOC (IN:[551..553] at)
        (NP
          (NP
            (NP (DT:[554..557] the) (NN:[558..571] juxtamembrane)
              (NML-1 (-NONE-:[571..571] *P*)))
            (CC:[572..575] and)
            (NP (DT:[576..579] the) (JJ:[580..585] first)
              (NML (NN:[587..595] tyrosine) (NN:[596..602] kinase))
              (NML-1 (NNS:[603..610] domains))))
          (PP (IN:[611..613] of)
            (NP
              (NP (NN:[614..618] FLT3))
              (PP-LOC (IN:[619..621] in)
                (NP
                  (NP (CD:[622..627] seven))
                  (PP (IN:[628..630] of)
                    (NP
                      (NP (CD:[631..633] 92)
                        (PRN (-LRB-:[634..635] -LRB-)
                          (NP (CD:[635..636] 8) (NN:[636..637] %))
                          (-RRB-:[637..638] -RRB-))
                        (NNS:[639..647] patients))
                      (PP (IN:[648..652] with)
                        (NP
                          (NP
                            (NP
                              (NP (JJ:[654..669] myelodysplastic)
                                  (NN:[670..678] syndrome))
                              (NP (-LRB-:[679..680] -LRB-) (NN:[680..683] MDS)
                                  (-RRB-:[683..684] -RRB-)))
                            (CC:[685..688] and)
                            (NP
                              (NP
                                (NP (NN:[689..692] AML))
                                (PP (IN:[693..697] with)
                                  (NP (NN:[698..708] trilineage)
                                      (NN:[709..723] myelodysplasia))))
                              (NP (-LRB-:[725..726] -LRB-) (NN:[726..729] AML)
                                (PP (SYM:[729..730] /)
                                  (NP (NN:[730..734] TMDS)))
                                (-RRB-:[734..735] -RRB-))))
                          (,:[735..736] ,)
                          (NP
                            (NP (DT:[737..740] the) (NNS:[741..749] diseases))
                            (SBAR
                              (WHNP-2 (WDT:[750..755] which))
                              (S
                                (NP-SBJ-2 (-NONE-:[755..755] *T*))
                                (VP (MD:[756..759] may)
                                  (VP (VB:[760..769] represent)
                                    (NP
                                      (NP (JJ:[770..780] neoplastic)
                                          (NNS:[781..788] changes))
                                      (PP (IN:[789..791] of)
                                        (NP (JJ:[792..803] pluripotent)
                                            (NN:[805..809] stem)
                                            (NNS:[810..815] cells))))))))))))))))))))
    (.:[815..816] .)))

;sentence 6 Span:817..1020
;A tandem duplication of exon 11 of FLT3 was harbored by two of 58  (3%)
;patients with MDS and five of 34 (15%) with overt leukemia, including 
;MDS-derived leukemia, AML/TMDS and therapy-related leukemia.
;[819..837]:variation-type:"tandem duplication"
;[841..848]:variation-location:"exon 11"
;[852..856]:gene-rna:"FLT3"
;[903..906]:malignancy:"MDS"
;[933..947]:malignancy:"overt leukemia"
;[960..980]:malignancy:"MDS-derived leukemia"
;[960..963]:malignancy:"MDS"
;[982..985]:malignancy:"AML"
;[986..990]:malignancy:"TMDS"
;[995..1019]:malignancy:"therapy-related leukemia"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[817..818] A)
         (JJ:[819..825] tandem) (NN:[826..837] duplication))
      (PP (IN:[838..840] of)
        (NP
          (NP (NN:[841..845] exon) (CD:[846..848] 11))
          (PP (IN:[849..851] of)
            (NP (NN:[852..856] FLT3))))))
    (VP (VBD:[857..860] was)
      (VP (VBN:[861..869] harbored)
        (NP-1 (-NONE-:[869..869] *))
        (PP (IN:[870..872] by)
          (NP-LGS
            (NP
              (NP (CD:[873..876] two))
              (PP (IN:[877..879] of)
                (NP
                  (NP (CD:[880..882] 58)
                    (PRN (-LRB-:[884..885] -LRB-)
                      (NP (CD:[885..886] 3) (NN:[886..887] %))
                      (-RRB-:[887..888] -RRB-))
                    (NNS:[889..897] patients))
                  (PP (IN:[898..902] with)
                    (NP (NN:[903..906] MDS))))))
            (CC:[907..910] and)
            (NP
              (NP (CD:[911..915] five))
              (PP (IN:[916..918] of)
                (NP
                  (NP (CD:[919..921] 34)
                    (PRN (-LRB-:[922..923] -LRB-)
                      (NP (CD:[923..925] 15) (NN:[925..926] %))
                      (-RRB-:[926..927] -RRB-)))
                  (PP (IN:[928..932] with)
                    (NP
                      (NP (JJ:[933..938] overt) (NN:[939..947] leukemia))
                      (,:[947..948] ,)
                      (PP (VBG:[949..958] including)
                        (NP
                          (NP
                            (ADJP (NN:[960..963] MDS) (HYPH:[963..964] -)
                                  (VBN:[964..971] derived))
                            (NN:[972..980] leukemia))
                          (,:[980..981] ,)
                          (NP (NN:[982..985] AML) (SYM:[985..986] /)
                              (NN:[986..990] TMDS))
                          (CC:[991..994] and)
                          (NP
                            (ADJP (NN:[995..1002] therapy) (HYPH:[1002..1003] -)
                                  (VBN:[1003..1010] related))
                            (NN:[1011..1019] leukemia)))))))))))))
    (.:[1019..1020] .)))

;sentence 7 Span:1021..1214
;Although the  duplicated regions varied within exon 11 in each case, they
;occurred in-frame,  and altered mRNA expressions were demonstrated by
;reverse-transcription  polymerase chain reaction.
;[1068..1075]:variation-location:"exon 11"
;[1188..1198]:gene-protein:"polymerase"
(SENT
  (S
    (S
      (SBAR-ADV (IN:[1021..1029] Although)
        (S
          (NP-SBJ (DT:[1030..1033] the) (VBN:[1035..1045] duplicated)
                  (NNS:[1046..1053] regions))
          (VP (VBD:[1054..1060] varied)
            (PP (IN:[1061..1067] within)
              (NP (NN:[1068..1072] exon) (CD:[1073..1075] 11)))
            (PP (IN:[1076..1078] in)
              (NP (DT:[1079..1083] each) (NN:[1084..1088] case))))))
      (,:[1088..1089] ,)
      (NP-SBJ (PRP:[1090..1094] they))
      (VP (VBD:[1095..1103] occurred)
        (ADVP-LOC (IN:[1104..1106] in) (HYPH:[1106..1107] -)
                  (NN:[1107..1112] frame))))
    (,:[1112..1113] ,) (CC:[1115..1118] and)
    (S
      (NP-SBJ-1 (VBN:[1119..1126] altered) (NN:[1127..1131] mRNA)
                (NNS:[1132..1143] expressions))
      (VP (VBD:[1144..1148] were)
        (VP (VBN:[1149..1161] demonstrated)
          (NP-1 (-NONE-:[1161..1161] *))
          (PP-MNR (IN:[1162..1164] by)
            (NP
              (NML (JJ:[1165..1172] reverse) (HYPH:[1172..1173] -)
                   (NN:[1173..1186] transcription))
              (NN:[1188..1198] polymerase) (NN:[1199..1204] chain)
               (NN:[1205..1213] reaction))))))
    (.:[1213..1214] .)))

;sentence 8 Span:1215..1307
;Two cases of MDS with a FLT3 duplication transformed  to overt leukemia
;within a few months.
;[1228..1231]:malignancy:"MDS"
;[1239..1243]:gene-rna:"FLT3"
;[1272..1286]:malignancy:"overt leukemia"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1215..1218] Two) (NNS:[1219..1224] cases))
      (PP (IN:[1225..1227] of)
        (NP
          (NP (NN:[1228..1231] MDS))
          (PP (IN:[1232..1236] with)
            (NP (DT:[1237..1238] a) (NN:[1239..1243] FLT3)
                (NN:[1244..1255] duplication))))))
    (VP (VBD:[1256..1267] transformed)
      (PP (TO:[1269..1271] to)
        (NP (JJ:[1272..1277] overt) (NN:[1278..1286] leukemia)))
      (PP-TMP (IN:[1287..1293] within)
        (NP (DT:[1294..1295] a) (JJ:[1296..1299] few) (NNS:[1300..1306] months))))
    (.:[1306..1307] .)))

;sentence 9 Span:1308..1547
;Longitudinal analyses in two other  patients with leukemia revealed that the
;duplication was a late genetic event  during the disease course; one of whom
;showed two independent duplications of  FLT3 at the terminal
;therapy-resistant phase.
;[1358..1366]:malignancy:"leukemia"
;[1385..1396]:variation-type:"duplication"
;[1485..1497]:variation-type:"duplications"
;[1502..1506]:gene-rna:"FLT3"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1308..1320] Longitudinal) (NNS:[1321..1329] analyses))
      (PP (IN:[1330..1332] in)
        (NP
          (NP (CD:[1333..1336] two) (JJ:[1337..1342] other)
              (NNS:[1344..1352] patients))
          (PP (IN:[1353..1357] with)
            (NP (NN:[1358..1366] leukemia))))))
    (VP (VBD:[1367..1375] revealed)
      (SBAR (IN:[1376..1380] that)
        (S
          (NP-SBJ (DT:[1381..1384] the) (NN:[1385..1396] duplication))
          (VP (VBD:[1397..1400] was)
            (NP-PRD
              (NP
                (NP (DT:[1401..1402] a) (JJ:[1403..1407] late)
                    (JJ:[1408..1415] genetic) (NN:[1416..1421] event))
                (PP-TMP (IN:[1423..1429] during)
                  (NP (DT:[1430..1433] the) (NN:[1434..1441] disease)
                      (NN:[1442..1448] course))))
              (::[1448..1449] ;)
              (SBAR
                (WHNP-1
                  (NP (CD:[1450..1453] one))
                  (WHPP (IN:[1454..1456] of)
                    (WHNP (WP:[1457..1461] whom))))
                (S
                  (NP-SBJ-1 (-NONE-:[1461..1461] *T*))
                  (VP (VBD:[1462..1468] showed)
                    (NP
                      (NP (CD:[1469..1472] two) (JJ:[1473..1484] independent)
                          (NNS:[1485..1497] duplications))
                      (PP (IN:[1498..1500] of)
                        (NP (NN:[1502..1506] FLT3))))
                    (PP (IN:[1507..1509] at)
                      (NP (DT:[1510..1513] the) (JJ:[1514..1522] terminal)
                        (ADJP (NN:[1523..1530] therapy) (HYPH:[1530..1531] -)
                              (JJ:[1531..1540] resistant))
                        (NN:[1541..1546] phase)))))))))))
    (.:[1546..1547] .)))

;sentence 10 Span:1548..1690
;Of seven patients with the FLT3  duplication, six had abnormal karyotypes,
;and four harbored a point mutation of  the N-RAS and/or TP53 genes.
;[1575..1579]:gene-rna:"FLT3"
;[1581..1592]:variation-type:"duplication"
;[1643..1657]:variation-type:"point mutation"
;[1666..1671]:gene-rna:"N-RAS"
;[1679..1683]:gene-rna:"TP53"
(SENT
  (S
    (PP-TPC-1 (IN:[1548..1550] Of)
      (NP
        (NP (CD:[1551..1556] seven) (NNS:[1557..1565] patients))
        (PP (IN:[1566..1570] with)
          (NP (DT:[1571..1574] the) (NN:[1575..1579] FLT3)
              (NN:[1581..1592] duplication)))))
    (,:[1592..1593] ,)
    (S
      (NP-SBJ
        (NP (CD:[1594..1597] six))
        (PP-1 (-NONE-:[1597..1597] *T*)))
      (VP (VBD:[1598..1601] had)
        (NP (JJ:[1602..1610] abnormal) (NNS:[1611..1621] karyotypes))))
    (,:[1621..1622] ,) (CC:[1623..1626] and)
    (S
      (NP-SBJ
        (NP (CD:[1627..1631] four))
        (PP-1 (-NONE-:[1631..1631] *T*)))
      (VP (VBD:[1632..1640] harbored)
        (NP
          (NP (DT:[1641..1642] a)
             (NN:[1643..1648] point) (NN:[1649..1657] mutation))
          (PP (IN:[1658..1660] of)
            (NP (DT:[1662..1665] the)
              (NML
                (NML (NN:[1666..1671] N-RAS)
                  (NML-2 (-NONE-:[1671..1671] *P*)))
                (CC:[1672..1678] and/or)
                (NML (NN:[1679..1683] TP53)
                  (NML-2 (NNS:[1684..1689] genes)))))))))
    (.:[1689..1690] .)))

;sentence 11 Span:1691..1740
;Patients with FLT3 mutations have poor prognoses.
;[1705..1709]:gene-rna:"FLT3"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1691..1699] Patients))
      (PP (IN:[1700..1704] with)
        (NP (NN:[1705..1709] FLT3) (NNS:[1710..1719] mutations))))
    (VP (VBP:[1720..1724] have)
      (NP (JJ:[1725..1729] poor) (NNS:[1730..1739] prognoses)))
    (.:[1739..1740] .)))

;sentence 12 Span:1742..1954
;This study uncovered the fact that the accumulation of genetic events,
;including  FLT3 duplication, correlates with leukemic transformation from
;antecedent  myelodysplasia and with subsequent disease progression.
;[1824..1828]:gene-rna:"FLT3"
;[1829..1840]:variation-type:"duplication"
;[1899..1913]:malignancy:"myelodysplasia"
(SENT
  (S
    (NP-SBJ (DT:[1742..1746] This) (NN:[1747..1752] study))
    (VP (VBD:[1753..1762] uncovered)
      (NP (DT:[1763..1766] the) (NN:[1767..1771] fact)
        (SBAR (IN:[1772..1776] that)
          (S
            (NP-SBJ
              (NP (DT:[1777..1780] the) (NN:[1781..1793] accumulation))
              (PP (IN:[1794..1796] of)
                (NP
                  (NP (JJ:[1797..1804] genetic) (NNS:[1805..1811] events))
                  (,:[1811..1812] ,)
                  (PP (VBG:[1813..1822] including)
                    (NP (NN:[1824..1828] FLT3) (NN:[1829..1840] duplication))))))
            (,:[1840..1841] ,)
            (VP (VBZ:[1842..1852] correlates)
              (PP-CLR
                (PP (IN:[1853..1857] with)
                  (NP
                    (NP (JJ:[1858..1866] leukemic)
                        (NN:[1867..1881] transformation))
                    (PP (IN:[1882..1886] from)
                      (NP (JJ:[1887..1897] antecedent)
                          (NN:[1899..1913] myelodysplasia)))))
                (CC:[1914..1917] and)
                (PP (IN:[1918..1922] with)
                  (NP (JJ:[1923..1933] subsequent) (NN:[1934..1941] disease)
                      (NN:[1942..1953] progression)))))))))
    (.:[1953..1954] .)))

;section 13 Span:1958..2002
;PMID: 9305595 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1958..1962] PMID) (::[1962..1963] :) (CD:[1964..1971] 9305595)
        (NN:[1972..1973] -LSB-) (NNP:[1973..1979] PubMed) (::[1980..1981] -)
        (NN:[1982..1989] indexed) (IN:[1990..1993] for)
        (NNP:[1994..2002] MEDLINE-RSB-)))
